Compare Dow Jones Industrial Average ETF (DIA) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs Ginkgo Bioworks Holdings Inc — how do they compare? Dow Jones Industrial Average ETF trades at $513.25 (market cap $45.20B), while Ginkgo Bioworks Holdings Inc trades at $12.02 (market cap $763.64M). The key difference: Dow Jones Industrial Average ETF is far larger — about 59.2× Ginkgo Bioworks Holdings Inc's market cap, and Dow Jones Industrial Average ETF is more actively traded (4,095,368 versus 3,204,177). Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 103 Days and Ginkgo Bioworks Holdings Inc for 7 Days on average.
| DIA | DNA | |
|---|---|---|
Market Cap | $45.20B | $763.64M |
Volume | 4,095,368 | 3,204,177 |
52-Week High | $542.79 | $15.83 |
52-Week Low | $451.37 | $5.48 |
Typical Hold Time | 103 Days | 7 Days |
Sector | — | Health |
Enterprise Value | — | $865.59M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $511.02, down 0.68% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF provides exposure to the 30 blue-chip Dow Jones Industrial Average components, offering diversified large-cap value. Recent dividend distributions in 2026 provide income, while broader market sentiment reflects caution amid economic uncertainty and Federal Reserve policy focus.
The outlook for DIA hinges on the performance of the Dow 30 constituents, with potential upside from strong corporate earnings but risks from high bond yields and market volatility. As a passive ETF, its value tracks the index, making macroeconomic trends and interest rate expectations key drivers. Current technical weakness near support at $509 suggests near-term pressure, though long-term investors may find stability in its blue-chip holdings.
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
